dalteparin has been researched along with Adolescent Obesity in 3 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our current dosing practice of 40 mg SC for individuals with a BMI ≤50 kg/m(2) and 60 mg for individuals with a BMI ≥50 kg/m(2) resulted in anti-factor Xa activity that was sufficient for adequate thromboprophylaxis in adolescent bariatric surgical patients." | 2.80 | Use of Enoxaparin in Obese Adolescents During Bariatric Surgery--a Pilot Study. ( Mushtaq, A; Nadler, EP; van den Anker, JN; Vaughns, JD; Ziesenitz, VC, 2015) |
| "Current enoxaparin dosing guidelines in children are based on total body weight." | 1.72 | Optimal dosing of enoxaparin in overweight and obese children. ( Al-Sallami, H; Derbalah, A; Duffull, S; Job, K; Sherwin, CM, 2022) |
| " The changes in anti-factor Xa activity due to plasmapheresis altered the final enoxaparin dosage required to remain in the therapeutic range of 0." | 1.46 | Effect of Plasmapheresis on the Anti-Factor Xa Activity of Enoxaparin in an Obese Adolescent Patient. ( Higgins, KL; Noda, C; Rahawi, KW; Stultz, JS, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Derbalah, A | 1 |
| Duffull, S | 1 |
| Sherwin, CM | 1 |
| Job, K | 1 |
| Al-Sallami, H | 1 |
| Mushtaq, A | 1 |
| Vaughns, JD | 1 |
| Ziesenitz, VC | 1 |
| Nadler, EP | 1 |
| van den Anker, JN | 1 |
| Rahawi, KW | 1 |
| Higgins, KL | 1 |
| Noda, C | 1 |
| Stultz, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prophylactic Use of Enoxaparin in Morbidly Obese Adolescents During Bariatric Surgery[NCT01587781] | 12 participants (Actual) | Observational | 2011-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for dalteparin and Adolescent Obesity
| Article | Year |
|---|---|
Use of Enoxaparin in Obese Adolescents During Bariatric Surgery--a Pilot Study.
Topics: Adolescent; Anticoagulants; Bariatric Surgery; Chemoprevention; Drug Administration Schedule; Enoxap | 2015 |
2 other studies available for dalteparin and Adolescent Obesity
| Article | Year |
|---|---|
Optimal dosing of enoxaparin in overweight and obese children.
Topics: Anticoagulants; Child; Enoxaparin; Humans; Metabolic Clearance Rate; Overweight; Pediatric Obesity | 2022 |
Effect of Plasmapheresis on the Anti-Factor Xa Activity of Enoxaparin in an Obese Adolescent Patient.
Topics: Adolescent; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Pediatric Obesi | 2017 |